Evidence map›Paper›PMID 20008986›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2010

A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer.

Do Won Hwang, Hae Young Ko, Jung Hwan Lee, Hyungu Kang, Sung Ho Ryu, In Chan Song, Dong Soo Lee, Soonhag Kim

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 288 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Modular Fabrication of Bioorthogonal Nanozymes for Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Advances in aptamer-based nuclear imaging.European journal of nuclear medicine and molecular imaging · 2022
    Review
  13. Nanomaterial Probes for Nuclear Imaging.Nanomaterials (Basel, Switzerland) · 2022
    Review
  14. Article
  15. Review
  16. Article
  17. Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside.Pharmaceuticals (Basel, Switzerland) · 2020
    Review
  18. Article
  19. Review
  20. Present Scenario of Bioconjugates in Cancer Therapy: A Review.International journal of molecular sciences · 2019
    Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Do Won HwangProgram in Neuroscience, Seoul National University, Seoul, Korea.
Hae Young Ko
Jung Hwan Lee
Hyungu Kang
Sung Ho Ryu
In Chan Song
Dong Soo Lee
Soonhag Kim
Seoul National University · KRPohang University of Science and Technology · KRCHA University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe recent advances in molecular imaging techniques, using cancer-targeting nanoparticle probes, provide noninvasive tracking information on cancer cells in living subjects. Here, we report a multimodal cancer-targeted imaging system capable of concurrent fluorescence imaging, radionuclide imaging, and MRI in vivo.

methodsA cobalt-ferrite nanoparticle surrounded by fluorescent rhodamine (designated MF) within a silica shell matrix was synthesized with the AS1411 aptamer (MF-AS1411) that targets nucleolin (a cellular membrane protein highly expressed in cancer) using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC). This purified MF-AS1411 particle was bound with 2-(p-isothio-cyanatobenzyl)-1,4,7-triazacyclonane-1,4,7-triacetic acid (p-SCN-bn-NOTA) chelating agent and further labeled with (67)Ga-citrate (MFR-AS1411). The shape and size distribution of MFR-AS1411 were characterized by transmission electron microscope (TEM). The cellular distribution of the nucleolin protein using the MFR-AS1411 nanoparticle was detected by fluorescence confocal microscopy. Phantom MR images were obtained as the concentration of MFR-AS1411 increased, using a 1.5-T MRI scanner. In vivo (67)Ga radionuclide imaging and MRI were performed using a gamma-camera and a 1.5-T MR imager, respectively.

resultsTEM imaging revealed MF and MFR-AS1411 to be spheric and well dispersed. The purified MFR-AS1411 nanoparticle showed specific fluorescence signals in nucleolin-expressing C6 cells, compared with MFR-AS1411 mutant (MFR-AS1411mt)-treated C6 cells. The rhodamine fluorescence intensity and (67)Ga activity of MFR-AS1411 were enhanced in a dose-dependent manner as the concentration of MFR-AS1411 was increased. The (67)Ga radionuclide was detected in both thighs of the mice injected with MFR-AS1411, whereas the MFR-AS1411 mutant (MFR-AS1411mt) administration revealed rapid clearance via the bloodstream, demonstrating that MFR-AS1411 specifically targeted cancer cells. Bioluminescence images in the C6 cells, stably expressing the luciferase gene, illustrated the in vivo distribution. T2-weighted MR images of the same mice injected with MFR-AS1411 showed dark T2 signals inside the tumor region, compared with the MRI signal of the tumor region injected with MFR-AS1411mt particles.

conclusionWe developed a nanoparticle-based cancer-specific imaging probe using the AS1411 aptamer in vivo and in vitro. This multimodal targeting imaging strategy, using a cancer-specific AS1411 aptamer, can be used as a versatile imaging tool for specific cancer diagnosis.

Indexed as

OligodeoxyribonucleotidesRadiopharmaceuticalsAnimalsAptamers, NucleotideCell Line, TumorCitratesDrug DesignFluorescent DyesGalliumGliomaMagnetic Resonance ImagingMiceMice, NudeMicroscopy, ConfocalMicroscopy, Electron, TransmissionNanoparticlesAGRO 100Aptamers, NucleotideCitratesFluorescent DyesGalliumgallium citrateNucleolinOligodeoxyribonucleotidesPhosphoproteinsRadiopharmaceuticalsRhodaminesRNA-Binding Proteins

Identifiers

PMID20008986
OpenAlexW2106592331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.